Vaccines Redefined

This block contains code to allow dead links in the navigation to function properly. This block will not be visible on the live site.

DO NOT DELETE

Contact Us
800-658-2849

Investors

Press Release Archive


  • 08/09/2010
    AlphaVax’s Vector System Shows Potential for Cancer Immunotherapy click here >>
  • 01/19/2010
    AlphaVax Advances Filovirus Biodefense Vaccines click here >>
  • 09/01/2009
    AlphaVax Progresses H1N1 Influenza Vaccine click here >>
  • 07/17/2009
    AlphaVax Announces Results from Initial Testing of its H1N1 (Swine) Influenza Vaccine click here >>
  • 05/28/2009
    2009 IBC Meeting click here >>
  • 05/14/2009
    AlphaVax Announces Phase I/II Study of Active Cancer Immunotherapy click here >>
  • 05/13/2009
    AlphaVax Announces Promising Results in Melanoma Studies click here >>
  • 02/16/2009
    AlphaVax Announces New Vice President of Regulatory, Quality and Clinical Operations click here >>
  • 12/29/2008
    Novartis enters into exclusive agreement with AlphaVax for novel CMV vaccine candidate click here >>
  • 10/29/2008
    AlphaVax Presents Results from CMV Phase 1 Trial click here >>
  • 07/21/2008
    AlphaVax Announces Initiation of Chlamydia Vaccine Program click here >>
  • 06/06/2008
    AlphaVax Continues to Expand the Use of its Vaccine Platform click here >>
  • 04/17/2008
    AlphaVax Announces Initial Analysis of Data from CMV Phase 1 Clinical Trial click here >>
  • 01/30/2008
    AlphaVax Announces New CMV Advisory Board click here >>
  • 10/31/2007
    AlphaVax Announces Results from Phase 1 Influenza Vaccine Clinical Trial click here >>
  • 07/30/2007
    AlphaVax Announces Interim Results from Phase 1 Influenza Vaccine Clinical Trial click here >>
  • 07/10/2007
    AlphaVax Announces $3.6M Award to Develop New Adjuvant Technologies for Vaccines click here >>
  • 04/11/2007
    AlphaVax begins Clinical Trials with Vaccines for CMV and FLU click here >>
  • 03/13/2007
    In The Pipeline click here >> 02/19/2007 New Data Support AlphaVax's Vaccine for CMV click here >>
  • 02/02/2007
    AlphaVax Announces the Closing of its E Series Investment Offering click here >>
  • 01/29/2007
    AlphaVax Announces Clinical Trials for Influenza and CMV click here >>
  • 10/11/2006
    Parents of EEE victim raising money for disease research click here >>
  • 09/06/2006
    AlphaVax Announces Phase 1 Clinical Trial Results click here >>
  • 07/26/2006
    AlphaVax Granted Key Vaccine Manufacturing Patent in US click here >>
  • 05/10/2006
    Three NCBIO members serving on National BIO Committees click here >>
  • 04/05/2006
    Peter Young to Testify on BioShield click here >>
  • 11/11/2005
    The Triangle’s Fastest Growing Private Biotech Company click here >>
  • 10/21/2005
    Alphavax Announces Support of Senator Richard Burr's Legislation click here >>
  • 10/19/2005
    Alphavax Announces $3.3 Million Grant Award to Develop A Smallpox Vaccine click here >>
  • 06/03/2005
    AlphaVax Announces New Lease for Vaccine Manufacturing Operations click here >>
  • 05/01/2005
    Peter Young elected Chair of NCBIO click here >>
  • 04/10/2005
    AlphaVax Annouces NIH Award for Influenza Vaccine click here >>
  • 02/06/2005
    Gene Vaccine Protects Mice Against Development of Her2/neu Breast Cancer click here >>
  • 11/17/2004
    AlphaVax Annouces $4.8m Award for a SARS Vaccine click here >>
  • 06/04/2004
    AlphaVax Annouces New Vice President of Development click here >>
  • 03/25/2004
    AlphaVax Annouces New Manufacturing Initiative click here >>
  • 11/19/2003
    AlphaVax Names Jonathan Smith Chief Scientific Officer click here >>
  • 10/21/2003
    AlphaVax Annouces New $16.8 Million NIH Award click here >>
  • 09/05/2003
    AlphaVax Receives Two NIH Biodefense Grants click here >>
  • 08/22/2003
    AlphaVax Begins Human Clinical Trials of Novel Vaccine Technology click here >>
  • 07/12/2003
    Progenics and Cytogen Develop Novel Prostate Cancer Vaccine with AlphaVax click here >>
  • 06/26/2003
    AlphaVax Hires New Medical Director click here >>
  • 05/15/2003
    AlphaVax Annouces New Head of Discovery and New Facility click here >>
  • 04/03/2002
    AlphaVax Annouces $11 million in Series C click here >>
  • 03/04/2002
    AlphaVax signs Manufacturing Agreement click here >>
  • 02/28/2001
    AlphaVax announces $8.2 million in Series B click here >>
  • 02/03/2001
    Glaxo Wellcome VP, Peter F. Young, named as President of AlphaVax click here >>
  • 11/19/2000
    International AIDS Vaccine Initiative Announces Major Research Partnership with AlphaVax click here >>